Lodovico Terzi-di-Bergamo

TL;DR: The results provide the proof of concept that ct DNA may serve as a novel precision medicine biomarker in cHL, and propose ctDNA as a radiation-free tool to track residual disease that may integrate positron emission tomography imaging for the early identification of chemorefractory patients with cHL.

TL;DR: The majority of very low-risk patients remained free of progression after treatment and their hazard of relapse decreased after 4 years from FCR, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group.

TL;DR: Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo Rigolin,A

TL;DR: It is shown that the non-canonical nuclear factor-κB pathway is active in BIRC3-mutated cell lines and in primary CLL samples, as documented by the stabilization of MAP3K14 and by the nuclear localization of p52, and may be used as a new molecular predictor to select high-risk patients for novel frontline therapeutic approaches.

TL;DR: The application of ultra-deep-next generation sequencing (NGS) to track TP53 mutated subclones in CLL has shown that chronic lymphocytic leukemia (CLL) is composed of a mosaic of leukemic subpopulations, each defined by distinct genetic lesions.